follicular lymphoma

News

Bayer pulls Aliqopa from US for follicular lymphoma

Bayer has said it plans to withdraw its PI3K inhibitor Aliqopa from the US market as a treatment for follicular lymphoma (FL) after the drug failed a confirmatory trial, d

News

FDA starts swift review of Regeneron’s CD20 bispecific

The FDA has started a priority review of Regeneron’s CD20xCD3 bispecific antibody odronextamab, seeking a broader label than other drugs in the class.

News

AbbVie, Genmab eye label expansion for Epkinly

Just a month after AbbVie and Genmab got FDA approval for Epkinly in one form of non-Hodgkin’s lymphoma, the partners are now preparing to file for a second.

News

Roche claims US approval for lymphoma bispecific Lunsumio

The FDA has given a green light to Roche's CD20xCD3 bispecific antibody Lunsumio as a treatment for relapsed or refractory follicular lymphoma, following the lead of the European Commission

News

Troubled Nordic Nanovector "exploring strategic options"

Reeling from the recent failure of its lead product in a pivotal trial, Nordic Nanovector has formally started a restructuring process and called in investment bank Carnegie to help explore

News

FDA to decide on Roche's lymphoma drug Lunsumio before year-...

The FDA has granted a priority review to Roche's T-cell engager Lunsumio as a treatment for follicular lymphoma (FL), setting up a decision on the drug by 29 December.

Bayer pulls Aliqopa from US for follicular lymphoma

FDA starts swift review of Regeneron’s CD20 bispecific

AbbVie, Genmab eye label expansion for Epkinly

Roche claims US approval for lymphoma bispecific Lunsumio

Troubled Nordic Nanovector "exploring strategic options"

FDA to decide on Roche's lymphoma drug Lunsumio before year-...

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

follicular lymphoma

Editor's Picks